RESUMO
Accumulating evidence from retrospective studies demonstrate at least non-inferior performance when using AI algorithms with different strategies versus double-reading in mammography screening. In addition, AI algorithms for mammography screening can reduce work load by moving to single human reading. Prospective trials are essential to avoid unintended adverse consequences before incorporation of AI algorithms into UK's National Health Service (NHS) Breast Screening Programme (BSP). A stakeholders' meeting was organized in Newnham College, Cambridge, UK to undertake a review of the current evidence to enable consensus discussion on next steps required before implementation into a screening programme. It was concluded that a multicentre multivendor testing platform study with opt-out consent is preferred. AI thresholds from different vendors should be determined while maintaining non-inferior screening performance results, particularly ensuring recall rates are not increased. Automatic recall of cases using an agreed high sensitivity AI score versus automatic rule out with a low AI score set at a high sensitivity could be used. A human reader should still be involved in decision making with AI-only recalls requiring human arbitration. Standalone AI algorithms used without prompting maintain unbiased screening reading performance, but reading with prompts should be tested prospectively and ideally provided for arbitration.
Assuntos
Neoplasias da Mama , Detecção Precoce de Câncer , Humanos , Feminino , Inteligência Artificial , Neoplasias da Mama/diagnóstico por imagem , Estudos Prospectivos , Estudos Retrospectivos , Medicina Estatal , AlgoritmosRESUMO
OBJECTIVE: To make measurable improvements in the quality and cost of neonatal intensive care using a multidisciplinary collaborative quality improvement model. DESIGN: Interventional study. Patient demographic and clinical information for infants with birth weight 501 to 1500 g was collected using the Vermont Oxford Network Database for January 1, 1994 to December 31, 1997. SETTING: Ten self-selected neonatal intensive care units (NICUs) received the intervention. They formed 2 subgroups (6 NICUs working on infection, 4 NICUs working on chronic lung disease). Sixty-six other NICUs served as a contemporaneous comparison group. PATIENTS: Infants with birth weight 501 to 1500 g born at or admitted within 28 days of birth between 1994 and 1997 to the 6 study NICUs in the infection group (n = 3063) and the 66 comparison NICUs (n = 21 509); infants with birth weight 501 to 1000 g at the 4 study NICUs in the chronic lung disease group (n = 738). INTERVENTIONS: NICUs formed multidisciplinary teams that worked together under the direction of a trained facilitator over a 3-year period beginning in January 1995. They received instruction in quality improvement, reviewed performance data, identified common improvement goals, and implemented "potentially better practices" developed through analysis of the processes of care, literature review, and site visits. MAIN OUTCOME MEASURES: The rates of infection after the third day of life with coagulase-negative staphylococcal or other bacterial pathogens for infants with birth weight 501 to 1500 g, and the rates of oxygen supplementation or death at 36 weeks' adjusted gestational age for infants with birth weight 501 to 1000 g. RESULTS: Between 1994 and 1996, the rate of infection with coagulase-negative staphylococcus decreased from 22.0% to 16.6% at the 6 project NICUs in the infection group; the rate of supplemental oxygen at 36 weeks' adjusted gestational age decreased from 43.5% to 31.5% at the 4 NICUs in the chronic lung disease group. There was heterogeneity in the effects among the NICUs in both project groups. The changes observed at the project NICUs for these outcomes were significantly larger than those observed at the 66 comparison NICUs over the 4-year period from 1994 to 1997. CONCLUSION: We conclude that multidisciplinary collaborative quality improvement has the potential to improve the outcomes of neonatal intensive care.
Assuntos
Infecção Hospitalar/epidemiologia , Recém-Nascido de muito Baixo Peso , Unidades de Terapia Intensiva Neonatal/normas , Pneumopatias/epidemiologia , Garantia da Qualidade dos Cuidados de Saúde , Infecções Estafilocócicas/epidemiologia , Doença Crônica , Infecção Hospitalar/terapia , Humanos , Incidência , Recém-Nascido , Unidades de Terapia Intensiva Neonatal/economia , Pneumopatias/terapia , Avaliação de Resultados em Cuidados de Saúde , Estudos Prospectivos , Infecções Estafilocócicas/terapia , Taxa de Sobrevida , Vermont/epidemiologiaRESUMO
OBJECTIVE: To make measurable improvements in the quality and cost of neonatal intensive care using a multidisciplinary collaborative quality improvement model. DESIGN: Interventional study. Data on treatment costs were collected for infants with birth weight 501 to 1500 g for the period of January 1, 1994 to December 31, 1997. Data on resources expended by hospitals to conduct this project were collected in a survey for the period January 1, 1995 to December 31, 1996. SETTING: Ten self-selected neonatal intensive care units (NICUs) received the intervention. They formed 2 subgroups (6 NICUs working on infection, 4 NICUs working on chronic lung disease). Nine other NICUs served as a contemporaneous comparison group. PATIENTS: Infants with birth weight 501 to 1500 g born at or admitted within 28 days of birth between 1994 and 1997 to the 6 study NICUs in the infection group (N = 2993) and the 9 comparison NICUs (N = 2203); infants with birth weight 501 to 1000 g at the 4 study NICUs in the chronic lung disease group (N = 663) and the 9 comparison NICUs (N = 1007). INTERVENTIONS: NICUs formed multidisciplinary teams which worked together to undertake a collaborative quality improvement effort between January 1995 and December 1996. They received instruction in quality improvement, reviewed performance data, identified common improvement goals, and implemented "potentially better practices" developed through analysis of the processes of care, literature review, and site visits. MAIN OUTCOME MEASURES: Treatment cost per infant is the primary economic outcome measure. In addition, the resources spent by hospitals in undertaking the collaborative quality improvement effort were determined. RESULTS: Between 1994 and 1996, the median treatment cost per infant with birth weight 501 to 1500 g at the 6 project NICUs in the infection group decreased from $57 606 to $46 674 (a statistical decline); at the 4 chronic lung disease hospitals, for infants with birth weights 501 to 1000 g, it decreased from $85 959 to $77 250. Treatment costs at hospitals in the control group rose over the same period. There was heterogeneity in the effects among the NICUs in both project groups. Cost savings were maintained in the year following the intervention. On average, hospitals spent $68 206 in resources to undertake the collaborative quality improvement effort between 1995 and 1996. Two thirds of these costs were incurred in the first year, with the remaining third in the second year. The average savings per hospital in patient care costs for very low birth weight infants in the infection group was $2.3 million in the post-intervention year (1996). There was considerable heterogeneity in the cost savings across hospitals associated with participation in the collaborative quality improvement project. CONCLUSION: Cost savings may be achieved as a result of collaborative quality improvement efforts and when they occur, they appear to be sustainable, at least in the short run. In high-cost patient populations, such as infants with very low birth weights, cost savings can quickly offset institutional expenditures for quality improvement efforts.
Assuntos
Recém-Nascido de muito Baixo Peso , Unidades de Terapia Intensiva Neonatal/economia , Unidades de Terapia Intensiva Neonatal/normas , Garantia da Qualidade dos Cuidados de Saúde/economia , Doença Crônica , Controle de Custos , Feminino , Pesquisa sobre Serviços de Saúde , Custos Hospitalares , Humanos , Recém-Nascido , Infecções/terapia , Tempo de Internação/economia , Pneumopatias/terapia , Masculino , Modelos Econômicos , Taxa de Sobrevida , Estados UnidosRESUMO
OBJECTIVE: To determine whether a course of low-dose indomethacin therapy, when initiated within 24 hours of birth, would decrease ductal shunting in premature infants who received prophylactic surfactant in the delivery room. DESIGN: Ninety infants, with birth weights of 600 to 1250 gm, were entered into a prospective, randomized, controlled trial to receive either indomethacin, 0.1 mg/kg per dose, or placebo less than 24 hours and again every 24 hours for six doses. Echocardiography was performed on day 1 before treatment and on day 7, 24 hours after treatment. A hemodynamically significant patent ductus arteriosus (PDA) was confirmed with an out-of-study echocardiogram, and the nonresponders were treated with standard indomethacin or ligation. RESULTS: Forty-three infants received indomethacin (birth weight, 915 +/- 209 gm; gestational age, 26.4 +/- 1.6 weeks; 25 boys), and 47 received placebo (birth weight, 879 +/- 202 gm; gestational age, 26.4 +/- 1.8 weeks; 22 boys) (P = not significant). Of 90 infants, 77 (86%) had a PDA by echocardiogram on the first day of life before study treatment; 84% of these PDAs were moderate or large in size in the indomethacin-treated group compared with 93% in the placebo group. Nine of forty indomethacin-treated infants (21%) were study-dose nonresponders compared with 22 (47%) of 47 placebo-treated infants (p < 0.018). There were no significant differences between both groups in any of the long-term outcome variables, including intraventricular hemorrhage, duration of oxygen therapy, endotracheal intubation, duration of stay in neonatal intensive care unit, time to regain birth weight or reach full caloric intake, incidence of bronchopulmonary dysplasia, and survival. No significant differences were noted in the incidence of oliguria, elevated plasma creatinine concentration, thrombocytopenia, pulmonary hemorrhage, or necrotizing enterocolitis. CONCLUSION: The prophylactic use of low doses of indomethacin, when initiated in the first 24 hours of life in low birth weight infants who receive prophylactic surfactant in the delivery room, decreases the incidence of left-to-right shunting at the level of the ductus arteriosus.
Assuntos
Permeabilidade do Canal Arterial/prevenção & controle , Indometacina/administração & dosagem , Doenças do Prematuro/prevenção & controle , Peso ao Nascer , Eletrocardiografia , Feminino , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Masculino , Estudos Prospectivos , Surfactantes Pulmonares/uso terapêutico , Testes de Função Respiratória , Resultado do TratamentoRESUMO
The purpose of this study was to determine whether decreased Fc gamma RIII expression on the PMN of extremely low birth weight infants (ELBW) is due to decreased receptor synthesis or increased receptor shedding from the PMN surface. 42 ELBW, 12 larger infants and 14 adults were enrolled. Plasma and total cellular Fc gamma RIII were measured by ELISA, and PMN Fc gamma RIII expression was measured by flow cytometry. ELBW PMN plasma membrane expression of Fc gamma RIII as measured by log mean channel fluorescence (5.00 +/- 1.98 vs. 10.68 +/- 1.61, p < 0.050) and plasma Fc gamma RIII levels were both lower (7.5 +/- 6.1 vs. 82.4 +/- 64.8 nM, p < 0.05) than in adult controls. In follow-up studies, 14 ELBW (age = 29 +/- 14 days, range = 14-56 days) increased PMN expression of Fc gamma RIII (p < 0.001) but not plasma Fc gamma RIII. ELBW had lower total PMN-associated Fc gamma RIII than adults (2.3 +/- 0.9 vs. 6.8 +/- 2.2 ng/10(6) PMN, p = 0.006). ELBW's PMN produce less Fc gamma RIII than adults' PMN, and expression of this receptor is developmentally regulated.
Assuntos
Envelhecimento/imunologia , Recém-Nascido de muito Baixo Peso/imunologia , Neutrófilos/imunologia , Receptores de IgG/metabolismo , Adulto , Ensaio de Imunoadsorção Enzimática , Citometria de Fluxo , Humanos , Recém-NascidoRESUMO
OBJECTIVE: We characterized the natural history and true mortality of congenital diaphragmatic hernia (CDH) in newborn patients by identifying all infants born with this condition in a fixed geographic region over a 2-year period. We examined this population to determine the frequency of intrauterine diagnosis, the outcome of prenatally diagnosed infants, and the impact of deaths in infants with an unsuspected diagnosis (the "hidden mortality") on the overall outcome of this condition. DESIGN: This was a retrospective population survey of all infants born with CDH in Minnesota between June 1988 and June 1990. SETTING: All Minnesota birth and death records were reviewed to identify patients with the diagnosis of CDH. A separate survey of all level 3 intensive care nurseries was conducted and the record of each identified patient was reviewed. Extracorporeal membrane oxygenation was available throughout the study period. MAIN OUTCOME MEASURE: Survival to hospital discharge and short-term morbidity were examined for each patient. RESULTS: Survival was 60% (29/48). Eleven of 19 deaths occurred in patients born prematurely and/or with coexisting major anomalies. Eight percent (4/48) of patients died within the first hour of life prior to diagnosis (hidden mortality). Intrauterine diagnosis of CDH was made in 15 patients. Survival was 60% (9/15) in infants whose conditions were diagnosed in utero, a rate identical to that for infants whose conditions were diagnosed in the postnatal period (61% [20/33]). There was no relationship between age at fetal diagnosis and mortality. CONCLUSIONS: The hidden mortality of CDH was low. Almost half of the total mortality for CDH was associated with coexisting, additional anomalies. Patients who were not offered extracorporeal membrane oxygenation owing to prematurity, other major anomalies, or birth at a center that did not offer extracorporeal membrane oxygenation accounted for 84% (16/19) of deaths. These data will be useful for determining the impact of new therapeutic strategies on the mortality of CDH.
Assuntos
Hérnia Diafragmática/diagnóstico , Hérnias Diafragmáticas Congênitas , Diagnóstico Pré-Natal , Oxigenação por Membrana Extracorpórea , Feminino , Idade Gestacional , Hérnia Diafragmática/mortalidade , Humanos , Mortalidade Infantil , Recém-Nascido , Masculino , Prontuários Médicos , Minnesota/epidemiologia , Gravidez , Estudos Retrospectivos , Estatística como Assunto , Taxa de SobrevidaRESUMO
Nosocomial infections increase neonates' morbidity, hospital costs, and mortality. These infections occur most commonly in very low birth weight infants, who frequently required plastic intravascular catheters and parenteral nutrition. Diagnosis often relies on a combination of laboratory tests and nonspecific clinical signs. Criteria for diagnosing nosocomial infections have been published by the Centers for Disease Control (CDC) and should be used to standardize the identification of cases. Initial antibiotic therapy depends on (1) the bacterial species most likely to cause infection, (2) antibiotic resistance patterns in one's own hospital, (3) the patient's clinical condition, and (4) previous antibiotic therapy. Antibiotic coverage of both gram-positive and gram-negative bacteria is necessary. Following laboratory identification of the infecting organism and the antibiotic susceptibility results, the patient should be reevaluated and definitive therapy prescribed. Multiple antibiotics may be needed as definitive therapy if (1) the infecting organism is likely to develop resistant mutants during therapy (e.g., Pseudomonas species), (2) higher bactericidal serum activity is required than can usually be achieved with a single agent (e.g., enterococci, Listeria), (3) the patient is neutropenic or otherwise severely immunocompromised, or (4) blood cultures are persistently positive for bacteria despite appropriate therapy with a single agent. Attempts to prevent nosocomial bacteremias by routinely administering prophylactic vancomycin may hasten the development of vancomycin-resistant, coagulase-negative staphylococci or enterococci and should be avoided.
Assuntos
Antibacterianos/uso terapêutico , Infecções Bacterianas/tratamento farmacológico , Infecção Hospitalar/tratamento farmacológico , Terapia Intensiva Neonatal , Antibacterianos/administração & dosagem , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/microbiologia , Resistência Microbiana a Medicamentos , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Infecções por Bactérias Gram-Positivas/microbiologia , Humanos , Recém-NascidoRESUMO
Limits of viability of extremely premature infants have recently been addressed both in Europe and the United States. These reports, which demonstrate frequent adverse outcome of infants born before 26 weeks of gestation, have not considered the impact of surfactant therapy. We reviewed records of 445 infants born between 23 and 36 weeks gestation who were admitted to our nursery following the availability of surfactant treatment in 1986 through 1992. Two hundred and eighty-five infants were treated with surfactant (Survanta, Ross Laboratories) as part of controlled, prospective trials or as routine treatment under Food and Drug Administration approval. One hundred and fifty-six infants were unable to be treated with surfactant, as either they received placebo therapy during prospective trials or were born prior to approval of routine surfactant use in the United States. Four additional infants born following the commercial availability of surfactant did not receive surfactant therapy. Survival of untreated infants was 56% compared to 75% in treated infants (P < 0.001). Infants born at all gestational ages between 23 and 26 weeks had an increased likelihood of survival as a result of surfactant treatment. No differences in neurologic outcome between surfactant treated and non-treated infants were demonstrated at subsequent follow-up. We conclude that survival of extremely premature infants is improved following surfactant therapy and that subsequent neurologic outcome is not compromised as a result of this therapy.
Assuntos
Produtos Biológicos , Doenças do Prematuro/terapia , Surfactantes Pulmonares/uso terapêutico , Síndrome do Desconforto Respiratório do Recém-Nascido/terapia , Ensaios Clínicos como Assunto , Ensaios Clínicos Controlados como Assunto , Feminino , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Masculino , Estudos Retrospectivos , Resultado do TratamentoRESUMO
Little information is available regarding the effect of surfactant on outcome for infants born at or before 26 weeks of gestation. We addressed this issue by reviewing records of 310 infants born at gestational ages of 23 through 26 weeks who were admitted to our nursery from 1986, when surfactant was introduced, through 1990. Surfactant was administered to 154 infants (5 during a single-dose prevention study, 25 during a multiple-dose prevention study, 124 while receiving a Food and Drug Administration treatment investigational new drug); 156 infants were not treated with surfactant. Seventy-three percent of the treated infants survived, compared with 55% of the nontreated infants. Increased survival occurred at all gestational ages between 23 and 26 weeks but were greatest in infants born at 23 and 24 weeks. At follow-up, no differences in neurologic outcome were detected between surfactant-treated and nontreated infants. We conclude that surfactant use in extremely premature infants improves survival rates without increasing the proportion of impaired survivors.
Assuntos
Recém-Nascido de Baixo Peso , Doenças do Prematuro/mortalidade , Surfactantes Pulmonares/uso terapêutico , Síndrome do Desconforto Respiratório do Recém-Nascido/tratamento farmacológico , Desenvolvimento Infantil , Feminino , Seguimentos , Idade Gestacional , Humanos , Mortalidade Infantil , Recém-Nascido , Recém-Nascido Prematuro , Masculino , Análise Multivariada , Síndrome do Desconforto Respiratório do Recém-Nascido/mortalidade , Taxa de SobrevidaRESUMO
Routine ACT tests cannot distinguish between prolonged blood clotting due to heparin effect or acquired abnormalities of the coagulation system after a loading dose of heparin. The purpose of this study was to examine an ACT test that inactivates heparin with Heparinase allowing for ACT assessment with and without heparin effect (HR-ACT with/without Heparinase, HemoTec, Inc.). The HR-ACT values were compared with the standard OR procedure that employed the Hemochron ACT. Twenty pediatric patients undergoing cardiopulmonary bypass for repair of cardiac defects were examined. All comparative ACT values were obtained from the same blood sample. Five sampling times were examined: 1) A baseline ACT was obtained before heparin had been administered; 2) A pre bypass ACT after a single heparin dose; 3) On bypass; 4) A post protamine ACT at the conclusion of surgery; and 5) In the Intensive Care Unit (PICU), 1 hour post protamine. The HemoTec HR-ACT with Heparinase and HR-ACT tests differentiated clotting time results that reflected coagulation status without the heparin effect. It identified those patients on bypass who were less than 5 kg, with prolonged ACTs that were due in part to hemodilution despite efforts at hemoconcentration.
Assuntos
Ponte Cardiopulmonar , Polissacarídeo-Liases , Tempo de Coagulação do Sangue Total , Adolescente , Criança , Pré-Escolar , Feminino , Heparina Liase , Humanos , Lactente , Recém-Nascido , MasculinoRESUMO
A critical appraisal of four cohort studies examining the relationship between Ureaplasma urealyticum and chronic lung disease (CLD) of prematurity is presented. Three studies were concurrently conducted, but the fourth was conducted 4 years later when surfactant replacement was a widespread practice. Although infants were enrolled in all studies soon after birth before they had developed CLD, there were differences in patients population, the definition of colonization with U. urealyticum, neonatal management, and the definition of CLD of prematurity. Despite the differences, all four studies found an association between colonization and development of CLD of prematurity. A combined estimate of relative risk for the four studies was 1.91 (95% confidence interval, 1.54-2.37). When infants were categorized into groups by birth weight, the association was not observed in infants who weighed > 1,250 g. The association was also not observed in infants who weighed < 750 g, but the risk of CLD of prematurity in the uncolonized control group was already 82%. Because the cohort study design allows for the possibility that one or more additional factors associated with U. urealyticum may be the true cause(s) of CLD of prematurity, there is strong but not definitive evidence that U. urealyticum causes CLD of prematurity.
Assuntos
Displasia Broncopulmonar/etiologia , Infecções por Ureaplasma/etiologia , Ureaplasma urealyticum/patogenicidade , Peso ao Nascer , Feminino , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Troca Materno-Fetal , Gravidez , Complicações Infecciosas na Gravidez , Fatores de Risco , Infecções por Ureaplasma/complicações , Infecções por Ureaplasma/transmissãoRESUMO
This study examined the association between Ureaplasma urealyticum colonization and the development of chronic lung disease (CLD) in 93 premature infants who were treated with surfactant and who had birth weights < 1251 g. Nasopharyngeal and tracheal cultures for U. urealyticum were obtained at 2 +/- 1 and at 14 +/- 1 days after birth and were positive in 17 (18%) of 93 patients. Infants born vaginally were 4.5 times more likely to be colonized than were those born by cesarean section. Colonization with U. urealyticum was associated with 1.66 (95% confidence interval, 1.24-2.20, P = .024) times the risk of developing CLD and with a greater incidence of > or = 2+ polymorphonuclear leukocytes in the tracheal aspirate at 2 +/- 1 days of age compared with uncolonized infants (P = .025). We conclude that U. urealyticum colonization is associated with CLD even after surfactant treatment. The presence of U. urealyticum is also associated with inflammatory cells in the tracheal aspirate.
Assuntos
Displasia Broncopulmonar/etiologia , Infecções por Ureaplasma/complicações , Ureaplasma urealyticum , Displasia Broncopulmonar/tratamento farmacológico , Dexametasona/uso terapêutico , Feminino , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Recém-Nascido Prematuro , Masculino , Nasofaringe/microbiologia , Estudos Prospectivos , Surfactantes Pulmonares/uso terapêutico , Traqueia/microbiologia , Ureaplasma urealyticum/isolamento & purificação , Ureaplasma urealyticum/patogenicidadeRESUMO
This study measured Fc gamma receptor (FcR) expression on polymorphonuclear leukocytes (PMN) and monocytes from extremely premature infants. Flow cytometry was used to quantitate FcRIII [cluster of differention (CD) 16], FcRII (CD32), FcRI (CD64), CD14, and CD67 proteins on the PMN surface. Sixty-four premature infants with a mean gestational age +/- SD of 26 +/- 2 wk (birth weight = 847 +/- 217 g), 12 infants born at term (gestational age = 38 +/- 1 wk), and 37 adults were studied. Premature infants' PMN expressed less FcRIII, measured as mean log channel fluorescence (MCF), than did term infants or adults (MCF = 4.7 +/- 1.4, 6.1 +/- 1.0, and 8.8 +/- 1.8, respectively, p < 0.050). Premature infants also had a lower proportion of FcRIII-positive PMN than term infants or adults (mean +/- SEM = 0.83 +/- 0.02 versus 0.92 +/- 0.04 and 0.96 +/- 0.01, respectively, p < 0.050). FcRIII expression on PMN was positively associated with cell isolation procedures (p = 0.004), birth weight (p = 0.004), and postnatal age (p = 0.032). Premature infants also had lower PMN expression of FcRII when compared with adults and term infants (MCF = 2.4 +/- 0.6 versus 3.0 +/- 0.7 and 3.1 +/- 0.3, p < 0.050). Both premature and term infants had fewer FcRII positive PMN than did adults (mean +/- SEM = 0.90 +/- 0.09 and 0.89 +/- 0.07 versus 0.99 +/- 0.00, p < 0.050). Premature infants' monocytes also expressed significantly less FcRIII (MCF = 2.4 +/- 0.6 versus 3.4 +/- 0.9, p = 0.047) and FcRII (2.1 +/- 0.5 versus 2.9 +/- 0.6, p = 0.01) compared with adults. We conclude that extremely premature infants have decreased expression of FcRIII and FcRII on both their PMN and monocytes when compared with adults. The decrease in PMN FcRIII expression appears related to birth weight and chronologic age.
Assuntos
Antígenos de Neoplasias , Moléculas de Adesão Celular , Recém-Nascido Prematuro/imunologia , Receptores de IgG/metabolismo , Adulto , Antígenos CD/metabolismo , Antígenos de Diferenciação Mielomonocítica/metabolismo , Feminino , Humanos , Recém-Nascido , Receptores de Lipopolissacarídeos , Masculino , Glicoproteínas de Membrana/metabolismo , Monócitos/imunologia , Neutrófilos/imunologiaRESUMO
Previously reported activated clotting time (ACT) data in adults demonstrated higher values with the HemoTec LRACT (HT) and TriMed ACTivator (TM) techniques than with the Hemochron System P214/215 (HC) technique throughout a range of heparin concentrations. This study sought to determine if a difference exists in ACT values of neonatal patients receiving ECMO. ACTs were performed in nine neonatal ECMO patients using the HC, HT, and TM techniques. Techniques were compared for positive or negative direction of any prediction difference (bias), and the typical value of a difference (precision). Simultaneous, duplicate, morning, and afternoon ACT comparisons were obtained using all three techniques. Forty-six comparisons of HC values in the 180-240 sec range were analyzed. All techniques produced results different from the same sample. The HT and TM techniques were upwardly biased by 51 and 148 sec, respectively, when evaluated against HC. HT was negatively biased by 123 sec when evaluated against TM. Because ACT values vary among techniques, ACT target ranges should be technique specific. Future references to ACT data should identify the equipment and procedures employed.
Assuntos
Oxigenação por Membrana Extracorpórea , Tempo de Coagulação do Sangue Total , Viés , Humanos , Recém-Nascido , Unidades de Terapia Intensiva Neonatal , Distribuição Aleatória , Reprodutibilidade dos TestesRESUMO
Theoretical advantages and risks exist for the use of both the centrifugal and roller pump systems in neonatal extracorporeal membrane oxygenation (ECMO). The authors studied the pressure-volume-flow relationships in clinically configured ECMO systems using these two pumps and a simulated patient to characterize differences in the circuit mechanics of the two systems, and thereby improve the design of subsequent clinical comparative trials of the pumps themselves. The relationship between flow and pressure generated across the pump was identical for the two systems. Within the range of clinically used flows, there was a direct relationship between pump revolution and flow with the roller pump, and between pump revolution and pressure generated for the centrifugal pump. Flow was limited in both systems by restrictions on negative pressure generating capacity. In the roller pump circuit, the venous reservoir (bladder box) assembly interrupted flow when negative pressure exceeded -20 mmHg; in the centrifugal pump system, forward flow stopped when negative pressure exceeded -100 mmHg. Volume had no detectable effect on the patient-pump inlet pressure gradient until critically low volumes were reached. At that point, removal of a few milliliters of volume led to large increases in the pressure gradient. The authors conclude that differences in pressure-volume-flow relationships between roller and centrifugal pump ECMO systems are due to the presence of the bladder box in the roller pump circuit. The advantages and disadvantages of the greater negative pressure in the centrifugal pump system require further study.
Assuntos
Oxigenação por Membrana Extracorpórea/instrumentação , Desenho de Equipamento , Hemodinâmica/fisiologia , Humanos , Recém-Nascido , Modelos Cardiovasculares , Modelos Estruturais , ReologiaAssuntos
Oxigenação por Membrana Extracorpórea , Hipertensão Pulmonar/terapia , Terapia Combinada , Feminino , Humanos , Hipertensão Pulmonar/diagnóstico , Recém-Nascido , Masculino , Recidiva , Síndrome do Desconforto Respiratório do Recém-Nascido/diagnóstico , Síndrome do Desconforto Respiratório do Recém-Nascido/terapiaRESUMO
From January 1986 through December 1988, we have seen 7 cases of isolated intestinal perforation in 250 infants with birth weights less than 1,000 g (3% incidence) without histological or clinical evidence of necrotizing enterocolitis (NEC). Patients had a mean birth weight of 670 g, gestational age of 25.1 weeks, and sustained a perforation at a chronological age of 10.4 days. No infants had been fed. A definite, blue-discolored abdomen was the only consistent clinical sign (n = 7). Free intraperitoneal air on radiograms was rarely observed (n = 1). Abdominal ultrasounds (n = 3) and metrizamide contrast studies (n = 3) were not diagnostic. The presence of an umbilical artery catheter (7/7), falling hematocrit (6/7), thrombocytopenia (5/7), and a positive diagnostic paracentesis were most commonly found. In 6 of 7 patients, this perforation was associated with coagulase-negative staphylococcal sepsis. Surgical or histological diagnosis showed focal perforation in either the terminal ileum (n = 4) or the transverse and descending colon (n = 3). Survival was 3 of 7; 2 patients died of intracranial hemorrhage and 2 died of Candida sepsis. We conclude that (1) intestinal perforation can occur in the absence of NEC; (2) bluish discoloration of the abdomen is the most reliable clinical finding; and (3) perforation may be associated with coagulase-negative staphylococcal infection.
Assuntos
Doenças do Colo/cirurgia , Doenças do Íleo/cirurgia , Recém-Nascido de Baixo Peso , Perfuração Intestinal/cirurgia , Doenças do Colo/etiologia , Feminino , Humanos , Doenças do Íleo/etiologia , Recém-Nascido , Perfuração Intestinal/etiologia , MasculinoRESUMO
This study compared the results of a commercially available, direct fluorescent antibody (DFA) test with viral culture in 880 specimens obtained from 690 patients by means of nasopharyngeal swabs. The two tests were congruent in 92.5% (814) of the specimens. The sensitivity of the DFA was 0.95, the specificity was 0.91, the positive predictive value was 0.82, and the negative predictive value was 0.98. Among 548 inpatients, there were 3 mixed infections (RSV and another virus), 8 RSV infections not identified by the DFA, and 35 positive DFA results not confirmed by cell culture. Use of the DFA test alone would have resulted in 502 (92%) correct patient-placement decisions. We conclude that the DFA test provides reliable evidence on which to base patient-placement decisions but that the error rate is too high to permit safe cohorting of high-risk patients, such as those with bronchopulmonary dysplasia.
Assuntos
Vírus Sinciciais Respiratórios/isolamento & purificação , Infecções por Respirovirus/microbiologia , Adolescente , Adulto , Criança , Pré-Escolar , Estudos de Coortes , Imunofluorescência , Humanos , Lactente , Recém-Nascido , Tempo de Internação , Minnesota , Valor Preditivo dos Testes , Infecções por Respirovirus/epidemiologiaRESUMO
Whole blood activated clotting time (ACT) can be determined by many different methods that use a variety of clotting cascade activators and end-points. This study compared the results of three whole blood ACT instruments at equivalent concentrations of heparin. Whole blood (9.8 ml) from 10 healthy adult volunteers without coagulation abnormalities was added to 0.2 ml of heparin solution producing heparin concentrations of 0, 0.1, 0.2, 0.4, 0.6, 0.8, and 1.0 U/ml. Coagulation status was determined in duplicate with the Hemochron 400 System (HC), the HemoTec Automated Coagulation Timer (HT), and the TriMed ACTivator (TM). Thrombin times or dilutions (TT) were also determined for each sample. Baseline values did not differ (p greater than 0.05); however, the HT and TM ACT values were significantly longer (p less than 0.05) than the HC ACT values at predicted heparin concentrations greater than 0.2 U/ml. Results from the HT and TM instruments were not significantly different. The HT and TM instruments both provided a greater ACT range over the heparin concentrations tested. Of the tests studied to monitor heparin therapy, mean scaled TTs showed the best correlation with predicted heparin concentrations.